Population
Patients with essential hypertension and diabetes mellitus
Design
Review
Authors
Loading...
Supports microalbuminuria screening for CV/renal risk in diabetes; leaves open ACE inhibitor benefits in normotensives pending RCTs.
Microalbuminuria is a key marker of cardiovascular and renal risk in hypertension and diabetes, and its progression can be mitigated by ACE inhibitors in diabetic patients.
Hans‐Henrik Parving (1996) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: